(QTRX) – Business Wire
-
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
-
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
-
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
-
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
-
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease
-
Quanterix to Present at Cowen’s 44th Annual Health Care Conference
-
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
-
Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Quanterix Releases Operating Results for Third Quarter 202
-
Quanterix to Report Third Quarter 2023 Financial Results on November 7, 2023
-
Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease
-
Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection
-
Quanterix CEO to Speak at Goldman Sachs Alzheimer’s Disease Day
-
Quanterix to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
-
William P. Donnelly Appointed to Quanterix’s Board of Directors
-
Quanterix Appoints Vandana Sriram as Chief Financial Officer
-
Quanterix Releases Operating Results for Second Quarter 2023
-
Quanterix to Present at Canaccord Genuity 43rd Annual Growth Conference
-
Quanterix’s Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients
-
Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023
-
Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer’s Disease in Patients
-
Quanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference
-
Quanterix Releases Operating Results for First Quarter 2023
-
Quanterix’s First Quarter 2023 Earnings Conference Call
-
FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials
-
Quanterix to Participate in Barclays Global Healthcare Conference
-
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations
-
Quanterix to Present at Cowen’s 43rd Annual Health Care Conference
-
Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call
-
Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call
-
Mercy BioAnalytics Announces Executive Leadership Changes
-
Quanterix Announces Appointment of Brian Blaser to Board of Directors
-
Quanterix Expands Laboratory Developed Test Menu with Launch of Neurofilament Light Chain Test
-
Quanterix to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
-
Quanterix to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force
-
Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
-
Quanterix Corporation Releases Operating Results for Third Quarter 2022
-
Quanterix’ Third Quarter 2022 Earnings Conference Call
-
Quanterix Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors
-
Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance
-
Quanterix to Participate in the Canaccord Genuity 42nd Annual Growth Conference
-
Quanterix’ Second Quarter 2022 Earnings Conference Call
-
Quanterix Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S.
-
Mercy BioAnalytics Appoints Dawn Mattoon, PhD, as Chief Operating Officer
-
Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
-
Quanterix Announces Appointment of Karen A. Flynn to Board of Directors
-
Quanterix Corporation Releases Operating Results for First Quarter 2022
-
Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022
Back to QTRX Stock Lookup
